Skip to content
drillr.ai

VCYT

Veracyte, Inc.

NASDAQ · USHealthcareBiotechnology
$57.26-3.16%

Price as of Jul 20, 2026

VCYT news

Veracyte, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

    Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 Veracyte, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.veracyte.com%2F&esheet=54567505&newsitemid=20260709945913&lan=en-US&anchor=Veracyte%2C+Inc.&index=1&md5=0e6d90f0a8d1fb672103a61a8bbc18e5) (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company m

    Business Wire ·

  2. ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

    ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher Prostate’s utility in high-risk localized disease Veracyte, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.veracyte.com%2F&esheet=54544412&newsitemid=20260530183615&lan=en-US&anc

    Business Wire ·

  3. Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

    Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study shows for the first time, based on the Prosigna test results, that more than two-thirds of patients could be spare

    Business Wire ·

  4. OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

    OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care Veracyte, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.veracyte.com%2F&esheet=54539751&newsitemid=20260521430337&lan=en-US&anchor=Veracyte%2C+Inc.&index=1&md5=abf5ef9fd8f9756

    Business Wire ·

  5. Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

    Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 Veracyte, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.veracyte.com%2F&esheet=54502280&newsitemid=20260414666656&lan=en-US&anchor=Veracyte%2C+Inc.&index=1&md5=3e857d21ae17a5e0cf841ce3fccc0f08) (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company manageme

    Business Wire ·

  6. Veracyte Names Kevin Haas as Chief Development and Technology Officer

    Veracyte Names Kevin Haas as Chief Development and Technology Officer Veracyte, Inc (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.veracyte.com%2F&esheet=54448269&newsitemid=20260316934398&lan=en-US&anchor=Veracyte%2C+Inc&index=1&md5=70fe99cff1ad6b4aca76a91de18f769f) . (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance

    Business Wire ·